PT-141 10 mg

DRAGON PHARMA PT-141

Dragon Pharma PT-141 (Bremelanotide) represents a revolutionary advancement in peptide-based sexual health therapeutics. Unlike traditional ED medications that work on vascular pathways, PT-141 operates centrally through the melanocortin system, offering a unique mechanism of action for men experiencing sexual dysfunction. This 10mg lyophilized powder formulation ensures maximum stability and potency, making it an ideal choice for athletes, bodybuilders, and fitness enthusiasts whose demanding lifestyles and supplement regimens may impact sexual performance.

DRUG COMPOSITION

Each 2mL vial contains 10mg of Bremelanotide acetate (PT-141), a synthetic heptapeptide analog of α-melanocyte-stimulating hormone (α-MSH). The product is presented as a sterile lyophilized powder without preservatives. The molecular formula is C₅₀H₆₈N₁₄O₁₀ with a molecular weight of 1025.2 g/mol. Dragon Pharma's manufacturing process ensures ≥98% purity through HPLC analysis, with no bacterial endotoxins detected.

PHARMACEUTICAL FORM

Sterile lyophilized powder in a 2mL glass vial with rubber stopper and aluminum seal. The powder appears as a white to off-white crystalline substance that readily reconstitutes with bacteriostatic water or sterile saline. The lyophilization process removes water while maintaining peptide integrity, ensuring extended shelf life and stability compared to liquid formulations.

PHARMACEUTICAL GROUP AND ATC CODE

PT-141 belongs to the therapeutic class "Other urogenital products" (G04BX). More specifically, it's classified as a melanocortin receptor agonist. Its ATC code is G04BX. Unlike PDE5 inhibitors (like sildenafil or tadalafil) which have the ATC code G04BE, PT-141 represents a distinct pharmacological approach to sexual dysfunction.

PHARMACOLOGICAL PROPERTIES

Bremelanotide (PT-141) is a synthetic melanocortin receptor agonist with particular affinity for MC4R and MC1R receptors in the central nervous system. Unlike peripheral-acting ED medications, PT-141 crosses the blood-brain barrier and activates neurons in the hypothalamus that regulate sexual arousal. This central mechanism stimulates dopamine pathways while inhibiting serotonin-mediated inhibitory signals, resulting in pro-sexual effects without direct vascular action. According to research published in the Journal of Sexual Medicine, PT-141 increases sexual desire in both men and women through this unique neuroendocrine pathway. The effects typically begin within 2 hours of administration and can last 6-8 hours, with no tachyphylaxis reported with occasional use.

THERAPEUTIC INDICATIONS

Dragon Pharma PT-141 10mg is indicated for the treatment of:

1. Hypoactive sexual desire disorder (HSDD) in men
2. Erectile dysfunction (ED) particularly of psychogenic or mixed etiology
3. Sexual dysfunction secondary to anabolic steroid use or post-cycle therapy
4. Diminished libido associated with aging, stress, or intensive training
5. SSRI-induced sexual dysfunction (off-label use)

The product is particularly valuable for bodybuilders and athletes experiencing sexual side effects from androgenic-anabolic steroid cycles, which can suppress natural testosterone production and libido despite maintained physical performance.

DOSES AND METHOD OF ADMINISTRATION

Reconstitution: Add 1-2mL of bacteriostatic water to the 10mg vial. Gently swirl (do not shake vigorously) until completely dissolved. The resulting solution contains 5-10mg/mL depending on the amount of diluent used.

Administration: Subcutaneous injection is the preferred route. Intranasal administration (off-label) is possible but has lower bioavailability (approximately 20% compared to 95% for subcutaneous).

Dosing:

• Initial dose: 1.0-1.5mg (0.1-0.15mL of 10mg/mL solution)
• Therapeutic dose: 1.75-2.0mg for most men
• Maximum dose: 2.5mg (not to exceed this amount)
• Frequency: As needed, not more than once every 24 hours or 8 times per month

Inject subcutaneously in the abdominal area, rotating injection sites. Effects typically begin within 45-120 minutes and last 6-8 hours. Start with the lowest effective dose and titrate upward based on response and tolerability.

CYCLE/STACKING

PT-141 can be effectively stacked with other Dragon Pharma products to address multiple aspects of sexual health, performance, and recovery:

1. With Cialis (Tadalafil): This combination addresses both central (PT-141) and peripheral (Cialis) mechanisms of sexual function. Cialis provides prolonged vasodilation while PT-141 enhances libido and arousal signals.
2. With Tesamorelin 5 mg: Tesamorelin helps reduce visceral fat which can improve hormone balance and sexual function, while PT-141 directly stimulates sexual desire.
3. With HCG 5000 IU: During or post steroid cycle, HCG restores testicular function while PT-141 counteracts libido suppression. This stack helps maintain sexual function during cutting or contest preparation phases.
4. With BPC-157: For athletes concerned with recovery, BPC-157 accelerates healing while PT-141 addresses potential libido issues from intense training or injury recovery periods.
5. With MK-677 (Ibutamoren): MK-677 enhances growth hormone secretion which can improve overall vitality, sleep quality, and recovery, complementing PT-141's sexual benefits.

Avoid stacking PT-141 with other centrally-acting sexual stimulants without medical supervision.

POST CYCLE THERAPY

PT-141 is particularly valuable during post-cycle therapy (PCT) when natural testosterone production is recovering. During this period, libido is often significantly diminished despite normalized hormone levels. PT-141 can bridge this gap by providing reliable sexual function while the hypothalamic-pituitary-testicular axis recovers. It can be used intermittently (1-2 times weekly) during PCT alongside traditional SERMs like Clomid or Nolvadex. Importantly, PT-141 does not interfere with gonadotropin secretion or testosterone recovery, making it compatible with standard PCT protocols.

SIDE EFFECTS

Most side effects are mild to moderate and dose-dependent:

• Common (10-20%): Facial flushing, mild nausea (usually transient), yawning, stretching sensations
• Less common (5-10%): Headache, injection site reactions, mild blood pressure elevation
• Rare (<1%): Spontaneous penile erections unrelated to sexual stimulation, dizziness, fatigue
• Darkening of skin or moles: As a melanocortin agonist, PT-141 can potentially darken existing pigmentation. Users should monitor moles and avoid sun exposure after administration.

Side effects typically diminish with continued use. Taking the medication on an empty stomach may reduce nausea.

CONTRAINDICATIONS

PT-141 is contraindicated in:

1. Patients with uncontrolled hypertension or cardiovascular disease
2. Individuals with a history of melanoma or atypical moles
3. Patients taking monoamine oxidase inhibitors (MAOIs)
4. Those with hypersensitivity to Bremelanotide or any component of the formulation
5. Patients with severe renal or hepatic impairment
6. Concurrent use with alcohol or recreational drugs

OVERDOSE

Doses exceeding 2.5mg significantly increase the incidence and severity of side effects, particularly nausea, vomiting, and blood pressure changes. There is no specific antidote for PT-141 overdose. Treatment is supportive and symptomatic. In case of accidental overdose, monitor blood pressure and provide antiemetics if needed. Severe hypertension may require medical intervention. Store PT-141 securely to prevent accidental use by others.

WARNINGS AND SPECIAL PRECAUTIONS FOR USE

1. Cardiovascular risk: Monitor blood pressure before and after administration, especially in individuals with hypertension.
2. Skin monitoring: Regular skin examinations are recommended due to potential melanocyte stimulation.
3. Psychiatric effects: Use with caution in individuals with psychiatric disorders as central melanocortin activation may affect mood.
4. Priapism risk: Although rare, prolonged erections (>4 hours) require immediate medical attention to prevent permanent damage.
5. Driving and operating machinery: May cause dizziness or vasovagal reactions; avoid until individual response is known.
6. Fertility: No studies on human fertility; animal studies show no impairment at therapeutic doses.
7. Bodybuilder considerations: Athletes using AAS should be aware that PT-141 does not replace proper PCT or address hormonal imbalances, only symptomatic sexual dysfunction.

INTERACTIONS WITH OTHER DRUGS

1. MAO inhibitors: Contraindicated due to potential hypertensive crisis.
2. PDE5 inhibitors (Viagra, Cialis): Additive effects on sexual function; monitor blood pressure.
3. Antihypertensives: May diminish blood pressure control.
4. Alcohol: Increases risk of nausea, hypotension, and vasovagal reactions.
5. Anabolic steroids: No direct interaction, but PT-141 may help counteract libido suppression from androgenic compounds.
6. SSRIs/SNRIs: PT-141 may help counteract sexual side effects of these antidepressants.

PRESENTATION, PACKAGING

Dragon Pharma PT-141 10mg is supplied as a single 2mL glass vial containing white lyophilized powder. Each vial is individually boxed with tamper-evident seal. Product includes batch number and expiration date on both vial and packaging. Professional multipacks are available for clinical or research use. The packaging includes a desiccant to maintain stability during shipping and storage.

STORAGE

Store unopened vials at 2-8°C (36-46°F) protected from light. Reconstituted solution is stable for 30 days when refrigerated at 2-8°C. Do not freeze reconstituted solution. Avoid temperature fluctuations. Discard any solution that appears cloudy or contains particles. For long-term storage of unopened vials, -20°C is acceptable but not required for the lyophilized powder.

DELIVERY TO THE USA

Dragon Pharma ships PT-141 10mg discreetly to all 50 states via express courier services. Domestic reshipping ensures reliable delivery and minimizes customs scrutiny. Orders typically arrive within 3-7 business days. Packaging is plain and unmarked for privacy. Tracking information is provided upon shipment. For research purposes only; not for human consumption per FDA regulations.

LEGAL STATUS

In the United States, Bremelanotide (PT-141) is approved by the FDA as Vyleesi® for premenopausal women with HSDD (prescription only). The lyophilized powder form sold for research purposes is not FDA-approved for any indication and is sold for laboratory research only. It is not a controlled substance under the CSA. Purchasers assume responsibility for compliance with local regulations. Bodybuilders and athletes should be aware that WADA prohibits PT-141 in competition.

DATE OF LAST TEXT CHECKS

/

NAME AND ADDRESS OF THE MANUFACTURER

Dragon Pharma, Europe

EXTERNAL LINKS

• NIH PubChem: Bremelanotide Chemical Information
• Melanocortin Receptor Agonists in Sexual Dysfunction: Clinical Review

PROFILE

• Chemical name: Acetyl-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH acetate
• Chemical formula: C₅₀H₆₈N₁₄O₁₀•C₂H₄O₂
• Percentage of anabolic activity: 0% (non-hormonal peptide)
• Percentage of androgenic activity: 0% (non-androgenic)
• Active half life: 2-3 hours (plasma); 6-8 hours (clinical effect duration)
• Recommended dosage: 1.75-2.0mg subcutaneously as needed
• Acne: Not associated (non-androgenic)
• Bloating (water retention): Not reported
• HBR: No hepatobiliary reactions reported
• Hepatic toxicity: None reported at therapeutic doses
• Aromatization: Does not aromatize (non-steroidal)